cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.27719219.v1
title: CD4+ T-cell transcription factors predict phenoconversion in idiopathic rapid eye movement sleep behavior disorder

description: <b>Aim:</b> Early biomarkers of phenoconversion to neurodegeneration are crucial to identify individuals at high risk. In patients with idiopathic REM sleep behavior disorder (iRBD), the strongest risk factor for neurodegeneration, CD4<sup>+</sup> T cells exhibit a peculiar transcription factor pattern. <b>Objective:</b> To assess transcription factor mRNA levels in CD4<sup>+</sup> T cells as predictive biomarkers of phenoconversion in iRBD patients. <b>Methods:</b> iRBD patients were followed prospectively. ROC curve analysis and Kaplan-Meier curves were used to assess the discrimination between converters and non-converters. <b>Results:</b> CD4<sup>+</sup> T cells from converters had higher <i>STAT1</i>, and lower <i>GATA3</i> and <i>FOXP3</i> mRNA levels. Hazard ratio was 58.3 (95% CI: 6.2–547.1) for higher <i>STAT1</i>, 101.2 (95% CI: 16.8–609.4) for lower <i>GATA3</i> and 15.7 (2.7–91.4) for lower <i>FOXP3</i>. <b>Conclusion:</b><i>STAT1</i>, <i>GATA3</i> and <i>FOXP3</i> mRNA levels in CD4<sup>+</sup> T cells are promising predictive biomarkers of phenoconversion in iRBD patients. Idiopathic REM sleep behavior disorder (iRBD) can lead to neurodegeneration, and the early identification of patients at risk would be crucial. Our research now shows that mRNA levels of some transcription factors in CD4<sup>+</sup> T cells may represent early biomarkers predicting phenoconversion to established neurodegenerative conditions on average up to 3.5 years earlier. Patients with idiopathic REM sleep behavior disorder (iRBD) are at risk of progression toward established neurodegeneration, and early biomarkers of phenoconversion would be crucial to identify individuals at higher risk. This study shows that, in iRBD subjects progressing to neurodegenerative conditions, CD4<sup>+</sup> T cells have higher expression of the transcription factors <i>STAT1</i>, and lower levels of <i>GATA3</i> and <i>FOXP3</i> on average 3.5 years before progression. <i>STAT1</i>, <i>GATA3</i> and <i>FOXP3</i> mRNA levels in CD4<sup>+</sup> T cells are therefore promising predictive biomarkers of phenoconversion in iRBD patients.
DOI: 10.6084/m9.figshare.27938175
title: Improvement of the rapid response system at an acute rehabilitation hospital in New Mexico

description: <b>Aim:</b> Enhance the Rapid Response System (RRS) in a free-standing acute rehabilitation hospital (ARH) by improving announcements, crash cart standardization and role assignments. <b>Materials & methods:</b> Pre-intervention (PreIQ) and post-intervention questionnaires (PostIQ), conducted in English and utilizing a Likert scale, were distributed in-person to clinical staff, yielding a 100% response rate. The questionnaire underwent no prior testing. The PreIQ were disseminated in February 2021, and PostIQ in December 2022. <b>Results:</b> PostIQ illustrated the improvement of audibility and improved the clarity of roles. The training positively impacted the RRS in the ARH. <b>Conclusion:</b> This study highlights the value of continuous RRS improvement in ARHs. Interventions led to notable enhancements, emphasizing the need for sustained efforts and future research on broader implementation. Thousands of in-hospital and out-of-hospital cardiac arrests occur annually. The Institute for Healthcare Improvement (IHI) launched the 100,000 Lives Campaign in 2004 which brought rise to the creation of rapid response teams (RRTs) within rapid response systems (RRS) to address rapid response cardiac arrest management. Studies have determined that a successful RRS consists of an afferent limb with a proper triggering system, an efferent limb with an experienced multidisciplinary team, and a hospital culture that embraces the RRS. In this study, the aim was to improve the RRS to rapid response events at a rehabilitation hospital in Albuquerque, New Mexico through quality improvement interventions in the following topics: rapid response announcements, crash cart stocks, and code response role assignments. Questionnaires were given to hospital clinical staff before implementation of the study to assess their opinion of the RRS as well as after to assess the impact of the interventions. Post-intervention questionnaire results illustrated improvements with rapid response announcements, code role assignments and hospital clinical staff training participation. The limitations of the study included the small sample size and limited duration of follow-up after the intervention. Continuous quality improvement can be an effective means of improving the RRS in hospitals, including rehabilitation hospitals.
DOI: 10.6084/m9.figshare.27938175.v1
title: Improvement of the rapid response system at an acute rehabilitation hospital in New Mexico

description: <b>Aim:</b> Enhance the Rapid Response System (RRS) in a free-standing acute rehabilitation hospital (ARH) by improving announcements, crash cart standardization and role assignments. <b>Materials & methods:</b> Pre-intervention (PreIQ) and post-intervention questionnaires (PostIQ), conducted in English and utilizing a Likert scale, were distributed in-person to clinical staff, yielding a 100% response rate. The questionnaire underwent no prior testing. The PreIQ were disseminated in February 2021, and PostIQ in December 2022. <b>Results:</b> PostIQ illustrated the improvement of audibility and improved the clarity of roles. The training positively impacted the RRS in the ARH. <b>Conclusion:</b> This study highlights the value of continuous RRS improvement in ARHs. Interventions led to notable enhancements, emphasizing the need for sustained efforts and future research on broader implementation. Thousands of in-hospital and out-of-hospital cardiac arrests occur annually. The Institute for Healthcare Improvement (IHI) launched the 100,000 Lives Campaign in 2004 which brought rise to the creation of rapid response teams (RRTs) within rapid response systems (RRS) to address rapid response cardiac arrest management. Studies have determined that a successful RRS consists of an afferent limb with a proper triggering system, an efferent limb with an experienced multidisciplinary team, and a hospital culture that embraces the RRS. In this study, the aim was to improve the RRS to rapid response events at a rehabilitation hospital in Albuquerque, New Mexico through quality improvement interventions in the following topics: rapid response announcements, crash cart stocks, and code response role assignments. Questionnaires were given to hospital clinical staff before implementation of the study to assess their opinion of the RRS as well as after to assess the impact of the interventions. Post-intervention questionnaire results illustrated improvements with rapid response announcements, code role assignments and hospital clinical staff training participation. The limitations of the study included the small sample size and limited duration of follow-up after the intervention. Continuous quality improvement can be an effective means of improving the RRS in hospitals, including rehabilitation hospitals.
DOI: 10.6084/m9.figshare.27719621
title: Green synthesized <i>Zingiber officinale</i>-ZnO nanoparticles: anticancer efficacy against 3D breast cancer model

description: <b>Aim:</b> ZnO NPs were prepared via green synthesis utilizing <i>Zingiber Officinale</i>. <b>Methodology:</b> Physical characterization and biological activity were performed against 2D, and 3D spheroids MCF-7 cell lines. <b>Results:</b> The NPs exhibited 188.9, 175.7 and 171.2 nm size with charge of -8.2, -11.7 and -9.7 mV for the 2%, 3% and 4% formulations. XRD confirmed a wurtzite hexagonal phase. FTIR spectra showed Zn-O stretching vibrations. The 2%, 3% and 4% formulations presented IC<sub>50</sub> values of 14.7, 26.2 and 47 μg/ml, respectively, with complete destruction of MCF-7 spheroids. Elevated <i>TNF-α</i> levels suggested an inflammatory-mediated mechanism of action. <b>Conclusion:</b> 2% <i>Zingiber officinale</i>-derived ZnO NPs showed antitumor potential against deserving further mechanistic and <i>in vivo</i> explorations. We created tiny particles from ginger extract to test their ability to fight breast cancer. These particles were carefully studied to understand their size, stability and structure. Our tests showed that these ginger-based particles effectively killed cancer cells in a more realistic 3D model, suggesting they might be a powerful new treatment for breast cancer. Further studies are needed to explore their potential use in real-life treatments. In this study we synthesized ZnO NPs via green synthesis utilizing <i>Zingiber Officinale</i>. ZnO NPs physical characterization and biological activity evaluation against 2D and 3D spheroids MCF-7 cell lines were performed. ZnO NPs showed an average sizes of 194.6, 188.9 and 171.2 nm for the 2%, 3% and 4% formulations, respectively. The XRD, EDX and SEM analyses affirmed the successful synthesis of nanoparticles with good morphology and size. The 2%, 3% and 4% formulations presented IC<sub>50</sub> values of 14.7, 26.2 and 47 μg/ml, respectively with complete destruction of MCF-7 spheroids. Elevated levels of <i>TNF-α</i> suggesting an inflammatory-mediated mechanism of action. 2% <i>Zingiber officinale</i>-derived ZnO NPs showed an outstanding antitumor potential against MCF-7 cells deserving further mechanistic and <i>in vivo</i> explorations.
DOI: 10.6084/m9.figshare.27719621.v1
title: Green synthesized <i>Zingiber officinale</i>-ZnO nanoparticles: anticancer efficacy against 3D breast cancer model

description: <b>Aim:</b> ZnO NPs were prepared via green synthesis utilizing <i>Zingiber Officinale</i>. <b>Methodology:</b> Physical characterization and biological activity were performed against 2D, and 3D spheroids MCF-7 cell lines. <b>Results:</b> The NPs exhibited 188.9, 175.7 and 171.2 nm size with charge of -8.2, -11.7 and -9.7 mV for the 2%, 3% and 4% formulations. XRD confirmed a wurtzite hexagonal phase. FTIR spectra showed Zn-O stretching vibrations. The 2%, 3% and 4% formulations presented IC<sub>50</sub> values of 14.7, 26.2 and 47 μg/ml, respectively, with complete destruction of MCF-7 spheroids. Elevated <i>TNF-α</i> levels suggested an inflammatory-mediated mechanism of action. <b>Conclusion:</b> 2% <i>Zingiber officinale</i>-derived ZnO NPs showed antitumor potential against deserving further mechanistic and <i>in vivo</i> explorations. We created tiny particles from ginger extract to test their ability to fight breast cancer. These particles were carefully studied to understand their size, stability and structure. Our tests showed that these ginger-based particles effectively killed cancer cells in a more realistic 3D model, suggesting they might be a powerful new treatment for breast cancer. Further studies are needed to explore their potential use in real-life treatments. In this study we synthesized ZnO NPs via green synthesis utilizing <i>Zingiber Officinale</i>. ZnO NPs physical characterization and biological activity evaluation against 2D and 3D spheroids MCF-7 cell lines were performed. ZnO NPs showed an average sizes of 194.6, 188.9 and 171.2 nm for the 2%, 3% and 4% formulations, respectively. The XRD, EDX and SEM analyses affirmed the successful synthesis of nanoparticles with good morphology and size. The 2%, 3% and 4% formulations presented IC<sub>50</sub> values of 14.7, 26.2 and 47 μg/ml, respectively with complete destruction of MCF-7 spheroids. Elevated levels of <i>TNF-α</i> suggesting an inflammatory-mediated mechanism of action. 2% <i>Zingiber officinale</i>-derived ZnO NPs showed an outstanding antitumor potential against MCF-7 cells deserving further mechanistic and <i>in vivo</i> explorations.
DOI: 10.6084/m9.figshare.27937858
title: A chemical approach facilitates CRISPRa-only human iPSC generation and minimizes the number of targeted loci required

description: <b>Aim:</b> We explored the generation of human induced pluripotent stem cells (iPSCs) solely through the transcriptional activation of endogenous genes by CRISPR activation (CRISPRa). <b>Methods:</b> Minimal number of human-specific guide RNAs targeting a limited set of loci were used with a unique cocktail of small molecules (CRISPRa-SM). <b>Results:</b> iPSC clones were efficiently generated by CRISPRa-SM, expressed general and naive iPSC markers and clustered with high-quality iPSCs generated using conventional reprogramming methods. iPSCs showed genomic stability and robust pluripotent potential as assessed by <i>in vitro</i> and <i>in vivo</i>. <b>Conclusion:</b> CRISPRa-SM-generated human iPSCs by direct and multiplexed loci activation facilitating a unique and potentially safer cellular reprogramming process to aid potential applications in cellular therapy and regenerative medicine. Combined chemical and CRISPRa-mediated approach leads to efficient generation of human iPSCs. Human iPSCs are conventionally derived through transient expression of exogenous reprogramming factors. We previously generated iPSCs from murine fibroblasts using SunTag-based CRISPRa method. With a minimal number of human-specific guide RNAs targeting a limited set of loci, combining CRISPRa with a unique cocktail of small molecules (CRISPRa-SM), bona fide iPSC colonies were successfully derived from human fibroblasts. iPSC clones expressed general and naive iPSC markers and clustered with high-quality iPSCs generated using conventional reprogramming methods. The CRISPRa-SM iPSCs displayed genomic stability and robust pluripotent potential as assessed by <i>in vitro</i> tri-lineage differentiation and <i>in vivo</i> teratoma assays. The CRISPRa-SM system generated human iPSCs by direct and multiplexed loci activation facilitating a unique and potentially safer cellular reprogramming process to aid potential applications in cellular therapy and regenerative medicine.
DOI: 10.6084/m9.figshare.27937858.v1
title: A chemical approach facilitates CRISPRa-only human iPSC generation and minimizes the number of targeted loci required

description: <b>Aim:</b> We explored the generation of human induced pluripotent stem cells (iPSCs) solely through the transcriptional activation of endogenous genes by CRISPR activation (CRISPRa). <b>Methods:</b> Minimal number of human-specific guide RNAs targeting a limited set of loci were used with a unique cocktail of small molecules (CRISPRa-SM). <b>Results:</b> iPSC clones were efficiently generated by CRISPRa-SM, expressed general and naive iPSC markers and clustered with high-quality iPSCs generated using conventional reprogramming methods. iPSCs showed genomic stability and robust pluripotent potential as assessed by <i>in vitro</i> and <i>in vivo</i>. <b>Conclusion:</b> CRISPRa-SM-generated human iPSCs by direct and multiplexed loci activation facilitating a unique and potentially safer cellular reprogramming process to aid potential applications in cellular therapy and regenerative medicine. Combined chemical and CRISPRa-mediated approach leads to efficient generation of human iPSCs. Human iPSCs are conventionally derived through transient expression of exogenous reprogramming factors. We previously generated iPSCs from murine fibroblasts using SunTag-based CRISPRa method. With a minimal number of human-specific guide RNAs targeting a limited set of loci, combining CRISPRa with a unique cocktail of small molecules (CRISPRa-SM), bona fide iPSC colonies were successfully derived from human fibroblasts. iPSC clones expressed general and naive iPSC markers and clustered with high-quality iPSCs generated using conventional reprogramming methods. The CRISPRa-SM iPSCs displayed genomic stability and robust pluripotent potential as assessed by <i>in vitro</i> tri-lineage differentiation and <i>in vivo</i> teratoma assays. The CRISPRa-SM system generated human iPSCs by direct and multiplexed loci activation facilitating a unique and potentially safer cellular reprogramming process to aid potential applications in cellular therapy and regenerative medicine.
DOI: 10.6084/m9.figshare.26976916
title: A consultation and work-up diagnosis protocol for a multicancer early detection test: a case series study

description: The emergence of multicancer early detection (MCED) tests holds promise for improving early cancer detection and public health outcomes. However, positive MCED test results require confirmation through recommended cancer diagnostic imaging modalities. To address these challenges, we have developed a consultation and work-up protocol for definitive diagnostic results post MCED testing, named SPOT-MAS. Developed through circulating tumor DNA (ctDNA) analysis and in line with professional guidelines and advisory board consensus, this protocol standardizes information to aid general practitioners in accessing, interpreting and managing SPOT-MAS results. Clinical effectiveness is demonstrated through a series of identified cancer cases. Our research indicates that the protocol could empower healthcare professionals to confidently interpret circulating tumor DNA test results for 5 common types of cancer, thereby facilitating the clinical integration of MCED tests. New tests can now screen for multiple types of cancer early, offering hope for better health outcomes. If one of these tests shows a positive result, doctors need to confirm it with imaging tests. We have developed a guide to help doctors understand and confirm these results. This guide could help healthcare professionals interpret results for five common types of cancer, making it easier to use these tests in regular medical practice. Developing a standard diagnostic follow-up protocol, known as Screening for the Presence Of Tumor by Methylation And Size (SPOT-MAS), to evaluate the performance of our multicancer early detection test and improve the clinical utility of liquid biopsy is essential for its widespread adoption and effectiveness in cancer diagnosis and management. The standard operating procedure ensures that appropriate steps are taken to achieve diagnostic resolution within a specified timeframe while providing comprehensive support and consultation for patients undergoing ctDNA analysis. To demonstrate the utility of our standard operating procedure in providing definitive diagnostic results to participants undertaking the SPOT-MAS test, a series of clinical cases were recorded in the K-DETEK study. This report presents a total of six clinical cases, including five true positive cases confirmed to have tumors at various stages in different organs (liver, lungs, breasts, colon and stomach) and one false positive case. The protocol ensures that healthcare professionals can confidently provide post-test consultation to SPOT-MAS test-takers across various clinical scenarios, paving the way for the application of the SPOT-MAS test in clinical settings.
DOI: 10.6084/m9.figshare.26976916.v1
title: A consultation and work-up diagnosis protocol for a multicancer early detection test: a case series study

description: The emergence of multicancer early detection (MCED) tests holds promise for improving early cancer detection and public health outcomes. However, positive MCED test results require confirmation through recommended cancer diagnostic imaging modalities. To address these challenges, we have developed a consultation and work-up protocol for definitive diagnostic results post MCED testing, named SPOT-MAS. Developed through circulating tumor DNA (ctDNA) analysis and in line with professional guidelines and advisory board consensus, this protocol standardizes information to aid general practitioners in accessing, interpreting and managing SPOT-MAS results. Clinical effectiveness is demonstrated through a series of identified cancer cases. Our research indicates that the protocol could empower healthcare professionals to confidently interpret circulating tumor DNA test results for 5 common types of cancer, thereby facilitating the clinical integration of MCED tests. New tests can now screen for multiple types of cancer early, offering hope for better health outcomes. If one of these tests shows a positive result, doctors need to confirm it with imaging tests. We have developed a guide to help doctors understand and confirm these results. This guide could help healthcare professionals interpret results for five common types of cancer, making it easier to use these tests in regular medical practice. Developing a standard diagnostic follow-up protocol, known as Screening for the Presence Of Tumor by Methylation And Size (SPOT-MAS), to evaluate the performance of our multicancer early detection test and improve the clinical utility of liquid biopsy is essential for its widespread adoption and effectiveness in cancer diagnosis and management. The standard operating procedure ensures that appropriate steps are taken to achieve diagnostic resolution within a specified timeframe while providing comprehensive support and consultation for patients undergoing ctDNA analysis. To demonstrate the utility of our standard operating procedure in providing definitive diagnostic results to participants undertaking the SPOT-MAS test, a series of clinical cases were recorded in the K-DETEK study. This report presents a total of six clinical cases, including five true positive cases confirmed to have tumors at various stages in different organs (liver, lungs, breasts, colon and stomach) and one false positive case. The protocol ensures that healthcare professionals can confidently provide post-test consultation to SPOT-MAS test-takers across various clinical scenarios, paving the way for the application of the SPOT-MAS test in clinical settings.
DOI: 10.6084/m9.figshare.26885546
title: Clinical treatment strategy and follow-up of lymphoepithelioma-like carcinoma: a retrospective study

description: <b>Aim:</b> To investigate the clinical features, diagnosis and treatment of lymphoepithelioma-like carcinoma (LELC). <b>Materials & methods:</b> The clinical data of 114 LELC patients were retrospectively analyzed. <b>Results:</b> Ninety-eight patients (86.0%) were Epstein-Barr virus-encoded small RNA (EBER) positive detected by situ hybridization. A 67.1% (51/76) patients had PD-L1 expression. The 5-year overall survival rate of EBER negative patients was 51.6% while the rate of positive patients was 84.8% (<i>p</i> = 0.015). The 5-year progression free survival rate of EBER negative patients was 40.2% while the rate of positive patients was 70.2% (<i>p</i> = 0.004). <b>Conclusion:</b> The progression of LELC is relatively slow and present a better prognosis. The occurrence of tumor is closely related to Epstein–Barr virus infection and PD-L1 is highly expressed in tumor cells. Lymphoepithelioma-like carcinoma (LELC) is a rare and special malignant tumor. The characteristics of it are not clear. We collected the data of 114 LELC patients. Then we found this tumor grew slowly. Eighty six percent of patients had been infected with EBV. Through microscopic observation, we found that 67.1% of patients had PD-L1 expression in tumor tissue. These characteristics can help people predict how long LELC patients will live and choose useful treatments. The progression of lymphoepithelioma-like carcinoma is relatively slow and present a better prognosis. Surgery is the main treatment. The occurrence of tumor is closely related to Epstein–Barr virus infection, and PD-L1 is highly expressed in tumor cells in most cases. The genomic variation spectrum is similar to nasopharyngeal carcinoma, which may benefit from immunotherapy.